SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On October 27, 2025, investors in Organon & Co. (NYSE: OGN) saw the price of their shares plummet $2.10 (-23%) after the company announced the findings of its Audit Committee's investigation into improper wholesale sales practices for Nexplanon and CEO Kevin Ali's resignation. The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Organon and its now-former CEO intentionall ...